Variation in total cholesterol, triglycerides linked to Alzheimer’s disease risk
Jul 06, 2023
Those in the highest quintile of total cholesterol and triglycerides had increased risk for Alzheimer’s disease and Alzheimer’s-related dementias.
Number of teeth, periodontitis in older adults linked to hippocampal atrophy
Jul 06, 2023
A qualitative interaction was seen between the number of teeth present and the mean periodontal probing depth for symmetric percentage change in left hippocampus.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Sleep-disordered breathing linked to medial temporal lobe atrophy in seniors
Jun 02, 2023
Higher sleep apnea severity was related to lower medial temporal lobe subregion volumes in amyloid-positive, but not amyloid-negative, individuals.
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Experimental drug for Alzheimer’s disease slows decline in thinking
May 03, 2023
Eli Lilly says the drug slows memory and thinking declines in early symptomatic Alzheimer’s disease patients by more than a third.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.